AQR Capital Management - EAGLE PHARMACEUTICALS INC ownership

EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 147 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
AQR Capital Management ownership history of EAGLE PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$4,462,248
-37.6%
282,958
-23.1%
0.01%
-40.0%
Q2 2023$7,153,395
-5.0%
367,973
+38.6%
0.02%
-11.8%
Q1 2023$7,529,965
+90.4%
265,420
+96.1%
0.02%
+88.9%
Q4 2022$3,955,257
+56.1%
135,315
+41.1%
0.01%
+50.0%
Q3 2022$2,534,000
+11.1%
95,915
+86.9%
0.01%
+20.0%
Q2 2022$2,280,000
+9.8%
51,316
+22.3%
0.01%
+25.0%
Q1 2022$2,077,000
-13.6%
41,963
-11.1%
0.00%0.0%
Q4 2021$2,405,000
-9.1%
47,225
-0.4%
0.00%
-20.0%
Q3 2021$2,646,000
+11.0%
47,434
-14.9%
0.01%
+25.0%
Q2 2021$2,384,000
-7.0%
55,707
-9.3%
0.00%0.0%
Q1 2021$2,563,000
+23.2%
61,409
+37.4%
0.00%0.0%
Q4 2020$2,081,000
-25.2%
44,685
-31.8%
0.00%
-20.0%
Q3 2020$2,782,000
-37.1%
65,499
-29.0%
0.01%
-28.6%
Q2 2020$4,424,000
-33.5%
92,199
-36.2%
0.01%
-36.4%
Q1 2020$6,652,000
-13.2%
144,617
+13.4%
0.01%
+22.2%
Q4 2019$7,660,000
+19.5%
127,496
+12.5%
0.01%
+12.5%
Q3 2019$6,409,000
+0.6%
113,301
-1.0%
0.01%
+14.3%
Q2 2019$6,370,000
+16.9%
114,406
+6.0%
0.01%
+16.7%
Q1 2019$5,451,000
+38.8%
107,954
+10.8%
0.01%
+20.0%
Q4 2018$3,926,000
-17.1%
97,435
+42.6%
0.01%0.0%
Q3 2018$4,738,000
+31.0%
68,344
+43.0%
0.01%
+25.0%
Q2 2018$3,616,000
+6.6%
47,795
-25.8%
0.00%0.0%
Q1 2018$3,393,000
-60.0%
64,390
-59.5%
0.00%
-55.6%
Q4 2017$8,487,000
-29.1%
158,869
-20.8%
0.01%
-35.7%
Q3 2017$11,966,000
+38.4%
200,634
+83.0%
0.01%
+27.3%
Q2 2017$8,649,000
+201.9%
109,637
+217.4%
0.01%
+175.0%
Q1 2017$2,865,000
+82.4%
34,547
+74.4%
0.00%
+100.0%
Q4 2016$1,571,000
+12.9%
19,804
-0.4%
0.00%0.0%
Q3 2016$1,391,000
+16.0%
19,875
-35.7%
0.00%0.0%
Q2 2016$1,199,000
-16.6%
30,899
-12.9%
0.00%
-33.3%
Q1 2016$1,437,000
-41.3%
35,476
+28.6%
0.00%
-25.0%
Q4 2015$2,447,000
-25.8%
27,597
-38.0%
0.00%
-42.9%
Q3 2015$3,297,000
+49.0%
44,534
+62.7%
0.01%
+75.0%
Q2 2015$2,213,000
+521.6%
27,372
+222.0%
0.00%
+300.0%
Q1 2015$356,0008,5000.00%
Other shareholders
EAGLE PHARMACEUTICALS INC shareholders Q2 2021
NameSharesValueWeighting ↓
ProQuest Associates IV LLC 4,780,188$353,877,00083.76%
JW Asset Management, LLC 848,709$62,830,00022.76%
Consonance Capital Management LP 1,353,913$100,230,00014.10%
Cormorant Asset Management, LP 300,000$22,209,0003.55%
Park West Asset Management LLC 500,591$37,059,0003.38%
Opaleye Management Inc. 73,200$5,419,0002.67%
Ranger Investment Management 428,295$31,707,0001.79%
WALL STREET ASSOCIATES 119,900$8,876,0001.70%
Timpani Capital Management LLC 27,090$2,005,0000.81%
ROSENBLUM SILVERMAN SUTTON S F INC /CA 22,375$1,656,0000.79%
View complete list of EAGLE PHARMACEUTICALS INC shareholders